The company's lead product candidate, dilanubicel (NLA101), is currently being evaluated in two ongoing Phase 2 clinical trials in adult and
pediatric patients with hematologic
malignancies undergoing an allogeneic transplant and adult patients receiving high dose chemotherapy
for Acute Myeloid Leukemia.
Recognizing a need to further explore genomic profiling in
pediatric malignancies, the Hugs
for Brady Foundation has committed $ 300,000 to the precision medicine initiative at Rutgers Cancer Institute of New Jersey.